
Theraclion S.A (ALTHE) | Financial Analysis & Statements
Theraclion S.A. | Small-cap | Healthcare
Theraclion S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
11.5M
Total Liabilities
11.5M
Shareholders Equity
-114
Cash Flow Metrics
Revenue & Profitability Trend
Theraclion S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 830.2K | 1.8M | 1.2M | 1.5M | 744.0K |
Cost of Goods Sold | 3.7M | 2.9M | 4.3M | 3.8M | 2.2M |
Gross Profit | -2.9M | -1.1M | -3.1M | -2.3M | -1.5M |
Gross Margin % | -346.0% | -59.3% | -246.9% | -154.2% | -201.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | - | - |
Other Operating Expenses | 396.7K | 701.1K | -54.6K | -76.1K | 287.3K |
Total Operating Expenses | 396.7K | 701.1K | -54.6K | -76.1K | 287.3K |
Operating Income | -6.8M | -3.1M | -6.3M | -5.3M | -4.2M |
Operating Margin % | -819.6% | -172.2% | -507.7% | -356.5% | -569.3% |
Non-Operating Items | |||||
Interest Income | 7.0K | 30.8K | - | - | - |
Interest Expense | 21.5K | 31.5K | 44.1K | 74.1K | 261.3K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -6.7M | -4.7M | -6.0M | -5.5M | -4.6M |
Income Tax | -983.7K | -1.0M | -1.0M | -882.6K | -722.5K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -5.8M | -3.7M | -5.0M | -4.6M | -3.9M |
Net Margin % | -693.5% | -201.7% | -401.8% | -313.9% | -524.9% |
Key Metrics | |||||
EBITDA | -5.9M | -2.4M | -6.1M | -5.3M | -3.9M |
EPS (Basic) | €-0.12 | €-0.08 | €-0.17 | €-0.17 | €-0.24 |
EPS (Diluted) | €-0.12 | €-0.08 | €-0.17 | €-0.17 | €-0.24 |
Basic Shares Outstanding | 46263670 | 45732250 | 29387612 | 22769085 | 16179830 |
Diluted Shares Outstanding | 46263670 | 45732250 | 29387612 | 22769085 | 16179830 |
Income Statement Trend
Theraclion S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 4.2M | 7.8M | 2.5M | 2.5M | 2.3M |
Short-term Investments | - | - | 31.1K | 31.1K | 31.1K |
Accounts Receivable | 267.8K | 3.1M | 2.2M | 1.2M | 1.4M |
Inventory | 2.1M | 3.1M | 3.1M | 2.6M | 2.2M |
Other Current Assets | -1 | - | 1 | -1 | - |
Total Current Assets | 8.3M | 16.1M | 9.3M | 7.9M | 7.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.7M | 128.1K | 177.6K | 45.5K | 952.6K |
Goodwill | 1.1M | 1.2M | 1.3M | 958.0K | 948.9K |
Intangible Assets | 1.1M | 1.2M | 1.3M | 958.0K | 948.9K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.9K | 11.7K | 13.3K | 25.5K | 57.5K |
Total Non-Current Assets | 3.2M | 2.6M | 4.6M | 3.9M | 3.6M |
Total Assets | 11.5M | 18.7M | 13.9M | 11.8M | 10.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.4M | 2.0M | 1.7M | 975.5K | 1.0M |
Short-term Debt | - | - | - | - | 72 |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 791.1K | 504.5K | 674.6K | 796.8K | 799.4K |
Total Current Liabilities | 3.7M | 4.6M | 4.3M | 3.5M | 3.1M |
Non-Current Liabilities | |||||
Long-term Debt | 1.3M | 2.0M | 2.5M | 2.9M | 4.1M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 6.3M | 6.3M | 6.5M | 6.6M | 6.5M |
Total Non-Current Liabilities | 7.7M | 8.5M | 9.1M | 9.6M | 10.7M |
Total Liabilities | 11.5M | 13.0M | 13.4M | 13.1M | 13.8M |
Equity | |||||
Common Stock | 2.3M | 2.3M | 1.5M | 1.1M | 809.0K |
Retained Earnings | -5.8M | -3.7M | -5.0M | -3.8M | -3.9M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -114 | 5.6M | 544.9K | -1.3M | -3.2M |
Key Metrics | |||||
Total Debt | 1.3M | 2.0M | 2.5M | 2.9M | 4.1M |
Working Capital | 4.5M | 11.6M | 5.0M | 4.4M | 3.9M |
Balance Sheet Composition
Theraclion S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -5.8M | -3.7M | -5.0M | -3.8M | -3.9M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 0 | 0 | 0 | 0 | -115.0K |
Operating Cash Flow | -5.8M | -3.7M | -5.0M | -3.7M | -3.8M |
Investing Activities | |||||
Capital Expenditures | -102.0K | -112.0K | -322.7K | -148.2K | -131.9K |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -102.0K | -113.0K | -322.7K | -148.1K | -131.9K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | 3.7M |
Debt Repayment | -655.0K | -784.0K | -442.0K | -1.2M | - |
Financing Cash Flow | -545.0K | 8.0M | 6.0M | 4.6M | 4.4M |
Free Cash Flow | -3.0M | -2.6M | -5.6M | -4.0M | -3.5M |
Net Change in Cash | -6.4M | 4.2M | 748.1K | 712.9K | 515.2K |
Cash Flow Trend
Theraclion S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-5.58
Forward P/E
6.58
Price to Sales
37.82
PEG Ratio
6.58
Profitability Ratios
Profit Margin
-346.01%
Operating Margin
-294.95%
Return on Equity
-203.90%
Return on Assets
-28.29%
Financial Health
Current Ratio
2.55
Debt to Equity
-66,510.16
Beta
-0.15
Per Share Data
EPS (TTM)
€-0.10
Book Value per Share
€0.00
Revenue per Share
€0.02
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
althe | 31.4M | -5.58 | - | -203.90% | -346.01% | -66,510.16 |
Guerbet S.A | 293.8M | 18.03 | 0.73 | 3.50% | 1.89% | 100.91 |
Eurobio Scientific | 251.9M | 64.36 | 1.41 | 2.26% | 2.58% | 5.46 |
Median Technologies | 91.7M | -1.84 | - | 74.31% | -109.93% | -0.98 |
Affluent Medical | 60.0M | -4.30 | 1.95 | -48.69% | -275.50% | 0.54 |
Novacyt S.A | 34.8M | -0.80 | 0.70 | -57.28% | -212.73% | 24.81 |
Financial data is updated regularly. All figures are in the company's reporting currency.